A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Inclusion Criteria:

1. Male or female aged 18-75 years old with diagnosis of CD for at least 30 days. InSouth Korea, the age requirement for adult participants is >=19 years of age.

2. Confirmed diagnosis of moderately to severely active CD assessed by SES-CD and CDAI.

3. Participants must have had an inadequate response to, loss of response to, orintolerance to at least one or more conventional, biologic, or advanced therapy forCD.

Exclusion Criteria:

1. Participants with indeterminate colitis, microscopic colitis, ischemic colitis,infectious colitis, radiation colitis, and diverticular disease associated withcolitis, and/or ulcerative colitis.

2. Have complications of CD that might require surgery during the study.

3. Participants with a current ostomy.

4. Participants who have failed 3 or more classes of advanced therapies.